Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anhydrous Ceftriaxone Sodium
2. Benaxona
3. Cefatriaxone
4. Cefaxona
5. Ceftrex
6. Ceftriaxon
7. Ceftriaxon Curamed
8. Ceftriaxon Hexal
9. Ceftriaxona Andreu
10. Ceftriaxona Ldp Torlan
11. Ceftriaxone
12. Ceftriaxone Irex
13. Ceftriaxone Sodium
14. Ceftriaxone Sodium, Anhydrous
15. Ceftriaxone, Disodium Salt
16. Ceftriaxone, Disodium Salt, Hemiheptahydrate
17. Lendacin
18. Longacef
19. Longaceph
20. Ro 13 9904
21. Ro 13-9904
22. Ro 139904
23. Ro-13-9904
24. Ro13 9904
25. Ro13-9904
26. Ro139904
27. Rocefalin
28. Rocefin
29. Rocephin
30. Rocephine
31. Tacex
32. Terbac
1. Ceftriaxone Sodium
2. Ceftriaxone
3. 74578-69-1
4. 104376-79-6
5. Ro-139904
6. Ceftriaxone Sodium Salt
7. Octx
8. Ceftriaxone Sodium Trihydrate
9. Schembl537013
10. Chembl1200995
11. Mfcd00941454
12. Akos015961150
13. Ac-1851
14. Disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
15. Sodium (6r,7r)-7-((e)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
16. Sodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
| Molecular Weight | 576.6 g/mol |
|---|---|
| Molecular Formula | C18H17N8NaO7S3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 8 |
| Exact Mass | 576.02800271 g/mol |
| Monoisotopic Mass | 576.02800271 g/mol |
| Topological Polar Surface Area | 291 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 1120 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Rocephin |
| PubMed Health | Ceftriaxone (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | Rocephin is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-t... |
| Active Ingredient | Ceftriaxone sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hoffmann La Roche |
| 2 of 2 | |
|---|---|
| Drug Name | Rocephin |
| PubMed Health | Ceftriaxone (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | Rocephin is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-t... |
| Active Ingredient | Ceftriaxone sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hoffmann La Roche |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DD - Third-generation cephalosporins
J01DD04 - Ceftriaxone
API SUPPLIERS
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32857
Submission : 2018-06-12
Status : Active
Type : II
Registrant Name : UK Chemical Farm Co., Ltd.
Registration Date : 2024-01-24
Registration Number : 20170413-116-G-139-13(7)
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd.
Manufacturer Address : Economy & Technological Development Zone, First Medical Zone, Datong, Shanxi, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33501
Submission : 2019-02-28
Status : Active
Type : II
Registrant Name : UK Chemical Farm Co., Ltd.
Registration Date : 2024-01-24
Registration Number : 20170413-116-G-139-13(7)
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd.
Manufacturer Address : Economy & Technological Development Zone, First Medical Zone, Datong, Shanxi, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29982
Submission : 2016-11-28
Status : Active
Type : II
Date of Issue : 2020-04-16
Valid Till : 2022-07-06
Written Confirmation Number : WC-0378A2
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33015
Submission : 2018-08-01
Status : Inactive
Type : II
Registrant Name : UK Chemical Farm Co., Ltd.
Registration Date : 2024-01-24
Registration Number : 20170413-116-G-139-13(7)
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd.
Manufacturer Address : Economy & Technological Development Zone, First Medical Zone, Datong, Shanxi, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24160
Submission : 2010-08-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20077
Submission : 2006-11-09
Status : Inactive
Type : II
Certificate Number : R1-CEP 2006-305 - Rev 03
Issue Date : 2022-07-15
Type : Chemical
Substance Number : 991
Status : Valid
Registration Number : 220MF10091
Registrant's Address : 174, Sirok-ro, Asan-si, Chungcheongnam-do, KOREA
Initial Date of Registration : 2008-03-28
Latest Date of Registration :
NDC Package Code : 51065-004
Start Marketing Date : 2012-07-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2018-01-23
Registration Number : 20180123-116-G-147-14
Manufacturer Name : (주)경보약약@[Raw product manufacturer]Sinopharm Weiqida Pharmaceutical Co. Ltd.@Henan Kangda Pharmaceutical Co., Ltd.
Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do @ [Production Factory] Economic & Technological Development Zone First Medical Zone, Datong, Shanxi, China. @ No.66 , Jingwu Road, Xiangcheng City, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17884
Submission : 2004-12-04
Status : Inactive
Type : II
Certificate Number : R1-CEP 2000-158 - Rev 05
Issue Date : 2019-07-02
Type : Chemical
Substance Number : 991
Status : Valid
Registration Number : 219MF10097
Registrant's Address : 57, Gyeongje-ro, Siheung-si, Gyeonggi-do, Korea
Initial Date of Registration : 2007-03-14
Latest Date of Registration :
Registrant Name : Hanmi Precision Chemical Co., Ltd.
Registration Date : 2009-09-24
Registration Number : 20090924-127-G-28-02
Manufacturer Name : Hanmi Precision Chemical Co., Ltd.
Manufacturer Address : 57 Gyeongje-ro, Siheung-si, Gyeonggi-do
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13656
Submission : 1998-09-01
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-084 - Rev 01
Issue Date : 2008-05-06
Type : Chemical
Substance Number : 991
Status : Valid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17259
Submission : 2004-03-25
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-07
Pay. Date : 2013-02-21
DMF Number : 17541
Submission : 2004-07-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17824
Submission : 2004-10-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13656
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17884
Submission : 2004-12-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15931
Submission : 2002-03-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17257
Submission : 2004-03-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17714
Submission : 2004-09-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16467
Submission : 2003-03-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4996
Submission : 1983-06-21
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Parenteral
Fillers, Diluents & Binders
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
91
PharmaCompass offers a list of Ceftriaxone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ceftriaxone manufacturer or Ceftriaxone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ceftriaxone manufacturer or Ceftriaxone supplier.
PharmaCompass also assists you with knowing the Ceftriaxone API Price utilized in the formulation of products. Ceftriaxone API Price is not always fixed or binding as the Ceftriaxone Price is obtained through a variety of data sources. The Ceftriaxone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ceftriaxone Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ceftriaxone Sodium, including repackagers and relabelers. The FDA regulates Ceftriaxone Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ceftriaxone Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ceftriaxone Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ceftriaxone Sodium supplier is an individual or a company that provides Ceftriaxone Sodium active pharmaceutical ingredient (API) or Ceftriaxone Sodium finished formulations upon request. The Ceftriaxone Sodium suppliers may include Ceftriaxone Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Ceftriaxone Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ceftriaxone Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Ceftriaxone Sodium active pharmaceutical ingredient (API) in detail. Different forms of Ceftriaxone Sodium DMFs exist exist since differing nations have different regulations, such as Ceftriaxone Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ceftriaxone Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Ceftriaxone Sodium USDMF includes data on Ceftriaxone Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ceftriaxone Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ceftriaxone Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ceftriaxone Sodium Drug Master File in Japan (Ceftriaxone Sodium JDMF) empowers Ceftriaxone Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ceftriaxone Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Ceftriaxone Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ceftriaxone Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ceftriaxone Sodium Drug Master File in Korea (Ceftriaxone Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ceftriaxone Sodium. The MFDS reviews the Ceftriaxone Sodium KDMF as part of the drug registration process and uses the information provided in the Ceftriaxone Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ceftriaxone Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ceftriaxone Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ceftriaxone Sodium suppliers with KDMF on PharmaCompass.
A Ceftriaxone Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Ceftriaxone Sodium Certificate of Suitability (COS). The purpose of a Ceftriaxone Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ceftriaxone Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ceftriaxone Sodium to their clients by showing that a Ceftriaxone Sodium CEP has been issued for it. The manufacturer submits a Ceftriaxone Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ceftriaxone Sodium CEP holder for the record. Additionally, the data presented in the Ceftriaxone Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ceftriaxone Sodium DMF.
A Ceftriaxone Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ceftriaxone Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ceftriaxone Sodium suppliers with CEP (COS) on PharmaCompass.
A Ceftriaxone Sodium written confirmation (Ceftriaxone Sodium WC) is an official document issued by a regulatory agency to a Ceftriaxone Sodium manufacturer, verifying that the manufacturing facility of a Ceftriaxone Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ceftriaxone Sodium APIs or Ceftriaxone Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Ceftriaxone Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Ceftriaxone Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ceftriaxone Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ceftriaxone Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ceftriaxone Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ceftriaxone Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ceftriaxone Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ceftriaxone Sodium suppliers with NDC on PharmaCompass.
Ceftriaxone Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ceftriaxone Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ceftriaxone Sodium GMP manufacturer or Ceftriaxone Sodium GMP API supplier for your needs.
A Ceftriaxone Sodium CoA (Certificate of Analysis) is a formal document that attests to Ceftriaxone Sodium's compliance with Ceftriaxone Sodium specifications and serves as a tool for batch-level quality control.
Ceftriaxone Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Ceftriaxone Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ceftriaxone Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Ceftriaxone Sodium EP), Ceftriaxone Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ceftriaxone Sodium USP).
